Incledon

Highland Therapeutics Announces New Chief Commercial Officer and Appointment of Chief Scientific Officer

Retrieved on: 
Thursday, September 17, 2020
Mental health, Research, FDA, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Ironshore, Liberty Mutual, Incledon, ADHD, JORNAY PM, Ironshore Pharmaceuticals Inc., Ironshore Pharmaceuticals & Development, Inc.

Mr. Danny Villeneuve has assumed the role of Executive Vice President and Chief Commercial Officer and Dr. Bev Incledon has been promoted to the role of Executive Vice President and Chief Scientific Officer at Ironshore Pharmaceuticals Inc. and Ironshore Pharmaceuticals & Development, Inc., respectively.

Key Points: 
  • Mr. Danny Villeneuve has assumed the role of Executive Vice President and Chief Commercial Officer and Dr. Bev Incledon has been promoted to the role of Executive Vice President and Chief Scientific Officer at Ironshore Pharmaceuticals Inc. and Ironshore Pharmaceuticals & Development, Inc., respectively.
  • I have no doubt Dr. Incledon will continue to excel in his role as Chief Scientific Officer.
  • Commenting on his appointment, Mr. Villeneuve said, I am excited to be joining Ironshore in the capacity of Chief Commercial Officer to help bring JORNAY PM to a broader audience of patients and prescribers.
  • Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Highland Therapeutics Inc. based in Toronto, Canada.